Roshani Mohammad, Rezaian-Isfahni Arya, Lotfalizadeh Mohammad Hassan, Khassafi Negar, Abadi Mohammad Hassan Jafari Najaf, Nejati Majid
Internal Medicine and Gastroenterology, Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.
Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Cancer Cell Int. 2023 Nov 19;23(1):280. doi: 10.1186/s12935-023-03115-1.
Gastrointestinal (GI) cancer is a major health problem worldwide, and current diagnostic and therapeutic approaches are often inadequate. Various metallic nanoparticles (MNPs) have been widely studied for several biomedical applications, including cancer. They may potentially overcome the challenges associated with conventional chemotherapy and significantly impact the overall survival of GI cancer patients. Functionalized MNPs with targeted ligands provide more efficient localization of tumor energy deposition, better solubility and stability, and specific targeting properties. In addition to enhanced therapeutic efficacy, MNPs are also a diagnostic tool for molecular imaging of malignant lesions, enabling non-invasive imaging or detection of tumor-specific or tumor-associated antigens. MNP-based therapeutic systems enable simultaneous stability and solubility of encapsulated drugs and regulate the delivery of therapeutic agents directly to tumor cells, which improves therapeutic efficacy and minimizes drug toxicity and leakage into normal cells. However, metal nanoparticles have been shown to have a cytotoxic effect on cells in vitro. This can be a concern when using metal nanoparticles for cancer treatment, as they may also kill healthy cells in addition to cancer cells. In this review, we provide an overview of the current state of the field, including preparation methods of MNPs, clinical applications, and advances in their use in targeted GI cancer therapy, as well as the advantages and limitations of using metal nanoparticles for the diagnosis and treatment of gastrointestinal cancer such as potential toxicity. We also discuss potential future directions and areas for further research, including the development of novel MNP-based approaches and the optimization of existing approaches.
胃肠道(GI)癌是全球主要的健康问题,目前的诊断和治疗方法往往并不充分。各种金属纳米颗粒(MNPs)已被广泛研究用于多种生物医学应用,包括癌症。它们有可能克服与传统化疗相关的挑战,并显著影响GI癌患者的总体生存率。带有靶向配体的功能化MNPs能更有效地定位肿瘤能量沉积,具有更好的溶解性和稳定性以及特异性靶向特性。除了增强治疗效果外,MNPs还是恶性病变分子成像的诊断工具,能够对肿瘤特异性或肿瘤相关抗原进行非侵入性成像或检测。基于MNP的治疗系统能使封装药物同时具备稳定性和溶解性,并将治疗剂直接递送至肿瘤细胞,从而提高治疗效果并将药物毒性和泄漏到正常细胞中的情况降至最低。然而,金属纳米颗粒已被证明在体外对细胞具有细胞毒性作用。在将金属纳米颗粒用于癌症治疗时,这可能是一个问题,因为它们除了癌细胞外还可能杀死健康细胞。在本综述中,我们概述了该领域的当前状态,包括MNPs的制备方法、临床应用以及它们在靶向GI癌治疗中的进展,以及使用金属纳米颗粒诊断和治疗胃肠道癌的优点和局限性,如潜在毒性。我们还讨论了潜在的未来方向和进一步研究的领域,包括新型基于MNP方法的开发和现有方法的优化。